Class information for: |
Basic class information |
| Class id | #P | Avg. number of references |
Database coverage of references |
|---|---|---|---|
| 35026 | 103 | 41.3 | 89% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
| 317 | 3 | HER2//TRASTUZUMAB//CHRONIC MYELOID LEUKEMIA | 39408 |
| 652 | 2 | HER2//TRASTUZUMAB//HER 2 NEU | 13568 |
| 35026 | 1 | M1B PROSTATE CANCER//BIOMARKER EPIDERMAL GROWTH FACTOR RECEPTOR EGFR//C ERB B 2 NEU GENE | 103 |
Terms with highest relevance score |
| rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|---|
| 1 | M1B PROSTATE CANCER | authKW | 592925 | 2% | 100% | 2 |
| 2 | BIOMARKER EPIDERMAL GROWTH FACTOR RECEPTOR EGFR | authKW | 296462 | 1% | 100% | 1 |
| 3 | C ERB B 2 NEU GENE | authKW | 296462 | 1% | 100% | 1 |
| 4 | CEDICINE | address | 296462 | 1% | 100% | 1 |
| 5 | CLINICAL TUMOR NODE METASTASES STAGE | authKW | 296462 | 1% | 100% | 1 |
| 6 | EGF R HER2 INHIBITORS | authKW | 296462 | 1% | 100% | 1 |
| 7 | ERB2 NEU | authKW | 296462 | 1% | 100% | 1 |
| 8 | HER2 AND EGFR | authKW | 296462 | 1% | 100% | 1 |
| 9 | HER2 NEU ONCOPROTEIN | authKW | 296462 | 1% | 100% | 1 |
| 10 | HYDROXIFLUTAMIDE | authKW | 296462 | 1% | 100% | 1 |
Web of Science journal categories |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | Oncology | 1066 | 52% | 0% | 54 |
| 2 | Urology & Nephrology | 638 | 23% | 0% | 24 |
| 3 | Pathology | 86 | 9% | 0% | 9 |
| 4 | Endocrinology & Metabolism | 30 | 8% | 0% | 8 |
| 5 | Andrology | 22 | 1% | 0% | 1 |
| 6 | Biotechnology & Applied Microbiology | 11 | 6% | 0% | 6 |
| 7 | Genetics & Heredity | 7 | 5% | 0% | 5 |
| 8 | Medicine, Research & Experimental | 5 | 4% | 0% | 4 |
| 9 | Cell Biology | 3 | 5% | 0% | 5 |
| 10 | Medical Laboratory Technology | 2 | 1% | 0% | 1 |
Address terms |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | CEDICINE | 296462 | 1% | 100% | 1 |
| 2 | PROSTATE VGH | 296462 | 1% | 100% | 1 |
| 3 | PATHOL BIOINFORMAT | 148230 | 1% | 50% | 1 |
| 4 | SANTO ANDRE | 148230 | 1% | 50% | 1 |
| 5 | UNIV SURG CANC SCI MOL PATHOL | 148230 | 1% | 50% | 1 |
| 6 | UROL COMPREHENS CANC | 148230 | 1% | 50% | 1 |
| 7 | ROENTGENOL RADIOL | 98819 | 1% | 33% | 1 |
| 8 | INVEST BIOMED AGUST PI SUNYER | 74114 | 1% | 25% | 1 |
| 9 | BASIC PL BIOL | 63146 | 7% | 3% | 7 |
| 10 | MINIST EDUC CANC PREVENT INTERVENT | 42350 | 1% | 14% | 1 |
Journals |
| Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
|---|---|---|---|---|---|
| 1 | TARGETED ONCOLOGY | 2867 | 2% | 0% | 2 |
| 2 | PROSTATE | 2346 | 6% | 0% | 6 |
| 3 | CANCER GENE THERAPY | 1358 | 3% | 0% | 3 |
| 4 | CLINICAL CANCER RESEARCH | 1274 | 8% | 0% | 8 |
| 5 | INTERNATIONAL JOURNAL OF UROLOGY | 821 | 3% | 0% | 3 |
| 6 | CANCER RESEARCH AND TREATMENT | 526 | 1% | 0% | 1 |
| 7 | HIPPOKRATIA | 488 | 1% | 0% | 1 |
| 8 | CELL CYCLE | 449 | 1% | 0% | 1 |
| 9 | CANCER BIOLOGY & THERAPY | 420 | 2% | 0% | 2 |
| 10 | CANCER | 381 | 6% | 0% | 6 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
| Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
|---|---|---|---|---|
| 1 | SIAMPANOPOULOU, M , GALAKTIDOU, G , DIMASIS, N , GOTZAMANI-PSARRAKOU, A , (2013) PROFILING SERUM HER-2/NEU IN PROSTATE CANCER.HIPPOKRATIA. VOL. 17. ISSUE 2. P. 108-112 | 20 | 43% | 4 |
| 2 | MINNER, S , JESSEN, B , STIEDENROTH, L , BURANDT, E , KOLLERMANN, J , MIRLACHER, M , ERBERSDOBLER, A , EICHELBERG, C , FISCH, M , BRUMMENDORF, TH , ET AL (2010) LOW LEVEL HER2 OVEREXPRESSION IS ASSOCIATED WITH RAPID TUMOR CELL PROLIFERATION AND POOR PROGNOSIS IN PROSTATE CANCER.CLINICAL CANCER RESEARCH. VOL. 16. ISSUE 5. P. 1553-1560 | 20 | 40% | 51 |
| 3 | DAI, B , KONG, YY , YE, DW , MA, CG , ZHOU, XY , YAO, XD , (2008) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR TYPE 2 PROTEIN EXPRESSION IN CHINESE METASTATIC PROSTATE CANCER PATIENTS CORRELATES WITH CANCER SPECIFIC SURVIVAL AND INCREASES AFTER EXPOSURE TO HORMONAL THERAPY.ASIAN JOURNAL OF ANDROLOGY. VOL. 10. ISSUE 5. P. 701 -709 | 12 | 67% | 7 |
| 4 | RICCIARDELLI, C , JACKSON, MW , CHOONG, CS , STAHL, J , MARSHALL, VR , HORSFALL, DJ , TILLEY, WD , (2008) ELEVATED LEVELS OF HER-2/NEU AND ANDROGEN RECEPTOR IN CLINICALLY LOCALIZED PROSTATE CANCER IDENTIFIES METASTATIC POTENTIAL.PROSTATE. VOL. 68. ISSUE 8. P. 830-838 | 18 | 38% | 21 |
| 5 | OKEGAWA, T , KINJO, M , NUTAHARA, K , HIGASHIHARA, E , (2006) PRETREATMENT SERUM LEVEL OF HER2/NUE AS A PROGNOSTIC FACTOR IN METASTATIC PROSTATE CANCER PATIENTS ABOUT TO UNDERGO ENDOCRINE THERAPY.INTERNATIONAL JOURNAL OF UROLOGY. VOL. 13. ISSUE 9. P. 1197-1201 | 13 | 57% | 18 |
| 6 | ZAHIR, ST , TAFTI, HF , RAHMANI, K , (2014) OVEREXPRESSION OF HER-2/NEU IN PATIENTS WITH PROSTATIC ADENOCARCINOMA.ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. VOL. 15. ISSUE 15. P. 6425 -6428 | 10 | 56% | 0 |
| 7 | TOBIUME, M , YAMADA, Y , NAKAMURA, K , AOKI, S , ZENNAMI, K , KATO, Y , NISHIKAWA, G , YOKOI, T , HONDA, N , (2011) SIGNIFICANT PROGNOSTIC FACTOR OF LMMUNOHISTOCHEMICAL HER-2 EXPRESSION USING INITIAL PROSTATE BIOPSY SPECIMENS WITH M1B PROSTATE CANCER.PROSTATE. VOL. 71. ISSUE 4. P. 385-393 | 13 | 39% | 2 |
| 8 | ZHANG, YF , GUAN, YB , YANG, B , WU, HY , DAI, YT , ZHANG, SJ , WANG, JP , ANOOPKUMAR-DUKIE, S , DAVEY, AK , SUN, ZY , (2011) PROGNOSTIC VALUE OF HER-2/NEU AND CLINICOPATHOLOGIC FACTORS FOR EVALUATING PROGRESSION AND DISEASE-SPECIFIC DEATH IN CHINESE MEN WITH PROSTATE CANCER.CHINESE MEDICAL JOURNAL. VOL. 124. ISSUE 24. P. 4345-4349 | 8 | 62% | 8 |
| 9 | DOMINGO-DOMENECH, J , FERNANDEZ, PL , FILELLA, X , MARTINEZ-FERNANDEZ, A , MOLINA, R , FERNANDEZ, E , ALCARAZ, A , CODONY, J , GASCON, P , MELLADO, B , (2008) SERUM HER2 EXTRACELLULAR DOMAIN PREDICTS AN AGGRESSIVE CLINICAL OUTCOME AND BIOLOGICAL PSA RESPONSE IN HORMONE-INDEPENDENT PROSTATE CANCER PATIENTS TREATED WITH DOCETAXEL.ANNALS OF ONCOLOGY. VOL. 19. ISSUE 2. P. 269-275 | 14 | 37% | 20 |
| 10 | GRAVINA, GL , FESTUCCIA, C , MILLIMAGGI, D , TORNBOLINI, V , DOLO, V , VICENTINI, C , BOLOGNA, M , (2009) BICALUTAMIDE DEMONSTRATES BIOLOGIC EFFECTIVENESS IN PROSTATE CANCER CELL LINES AND TUMOR PRIMARY CULTURES IRRESPECTIVE OF HER2/NEU EXPRESSION LEVELS.UROLOGY. VOL. 74. ISSUE 2. P. 452-457 | 8 | 62% | 2 |
Classes with closest relation at Level 1 |